AR030541A1 - Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica - Google Patents

Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica

Info

Publication number
AR030541A1
AR030541A1 ARP000106418A ARP000106418A AR030541A1 AR 030541 A1 AR030541 A1 AR 030541A1 AR P000106418 A ARP000106418 A AR P000106418A AR P000106418 A ARP000106418 A AR P000106418A AR 030541 A1 AR030541 A1 AR 030541A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical formulation
acids
amyinopropylphosphinic
medicines
Prior art date
Application number
ARP000106418A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0003640A external-priority patent/SE0003640D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR030541A1 publication Critical patent/AR030541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids R—P(OH)2; Thiophosphonous acids including RHP(=O)(OH); Derivatives thereof
    • C07F9/4808—Phosphonous acids R—P(OH)2; Thiophosphonous acids including RHP(=O)(OH); Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
    • C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Acidos aminopropilfosfínicos que tiene la formula (1) donde R1 representa hidrogeno, R2 representa hidroxi, fluor, o un grupo oxo; R3 representa hidrogeno; R4 representa hidrogeno; y las sales farmacéuticamente aceptables, solvatos y estereoisomeros de los mismos, con la excepcion del racemato del ácido (3-amino-2-hidroxipropil)fosfínico, su utilizacion para la manufactura de medicamentos y formulacion farmacéutica.
ARP000106418A 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica AR030541A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
SE0003640A SE0003640D0 (sv) 2000-10-09 2000-10-09 New compounds

Publications (1)

Publication Number Publication Date
AR030541A1 true AR030541A1 (es) 2003-08-27

Family

ID=26655259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106418A AR030541A1 (es) 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica

Country Status (33)

Country Link
US (5) US6576626B2 (es)
EP (2) EP1484333A1 (es)
JP (2) JP3914435B2 (es)
KR (1) KR100689144B1 (es)
CN (1) CN1198832C (es)
AR (1) AR030541A1 (es)
AT (1) ATE282043T1 (es)
AU (1) AU780459B2 (es)
BR (1) BR0016253A (es)
CA (1) CA2397583C (es)
CZ (1) CZ20021983A3 (es)
DE (1) DE60015796T2 (es)
DK (1) DK1240172T3 (es)
EE (1) EE05067B1 (es)
ES (1) ES2230174T3 (es)
HK (2) HK1048321B (es)
HU (1) HUP0300301A3 (es)
IL (2) IL149840A0 (es)
IS (1) IS2231B (es)
MX (1) MXPA02005536A (es)
MY (1) MY125414A (es)
NO (1) NO329595B1 (es)
NZ (1) NZ519376A (es)
PL (1) PL201789B1 (es)
PT (1) PT1240172E (es)
RU (1) RU2260595C2 (es)
SE (1) SE9904508D0 (es)
SI (1) SI1240172T1 (es)
SK (1) SK286904B6 (es)
TW (1) TWI228510B (es)
UA (1) UA71649C2 (es)
WO (1) WO2001042252A1 (es)
ZA (1) ZA200204127B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
WO2002062324A2 (en) * 2001-02-05 2002-08-15 Michael Albert Kamm A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
CA2632021A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
WO2007073298A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2155762B1 (en) * 2007-05-04 2011-10-12 AstraZeneca AB Process for the synthesis of alkyl phosphinic acids by initiation of an amine and an amineoxide
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2009082345A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form b of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a
WO2009082348A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form c of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy
EP2346885B1 (de) 2008-11-05 2013-08-28 Clariant International Ltd. Verfahren zur herstellung von monocarboxyfunktionaslisierten dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
WO2010051893A1 (de) 2008-11-07 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
CN102171226B (zh) 2008-11-11 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙基化合物制备单烯丙基官能化的二烷基次膦酸、其盐或酯的方法以及它们的用途
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
EP2379573B1 (de) 2008-12-18 2013-12-11 Clariant Finance (BVI) Limited Verfahren zur herstellung von ethylendialkylphosphinsäuren, -estern und -salzen mittels acetylen und ihre verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) * 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US4740332A (en) * 1986-05-12 1988-04-26 E. R. Squibb & Sons, Inc. Process for preparing phosphonous acids
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US5567840A (en) 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5281747A (en) 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL114631A (en) * 1990-06-22 1998-12-06 Novartis Ag Anti-epileptic preparations containing antagonists of BABAG
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
US20080146836A1 (en) 2008-06-19
NO329595B1 (no) 2010-11-22
CN1409716A (zh) 2003-04-09
BR0016253A (pt) 2002-08-27
TWI228510B (en) 2005-03-01
US20050137414A1 (en) 2005-06-23
MXPA02005536A (es) 2004-09-10
NZ519376A (en) 2003-11-28
EP1240172A1 (en) 2002-09-18
SK7642002A3 (en) 2002-12-03
RU2002113909A (ru) 2004-01-10
HK1048321B (zh) 2005-09-30
AU780459B2 (en) 2005-03-24
PL201789B1 (pl) 2009-05-29
CN1198832C (zh) 2005-04-27
CA2397583C (en) 2010-11-09
DE60015796D1 (de) 2004-12-16
SI1240172T1 (en) 2005-02-28
EE200200286A (et) 2003-08-15
DK1240172T3 (da) 2005-02-14
SE9904508D0 (sv) 1999-12-09
EP1240172B1 (en) 2004-11-10
NO20022728L (no) 2002-08-07
ATE282043T1 (de) 2004-11-15
WO2001042252A1 (en) 2001-06-14
RU2260595C2 (ru) 2005-09-20
IL149840A (en) 2006-04-10
UA71649C2 (en) 2004-12-15
ES2230174T3 (es) 2005-05-01
US7034176B2 (en) 2006-04-25
US20070021393A1 (en) 2007-01-25
EE05067B1 (et) 2008-08-15
ZA200204127B (en) 2003-08-25
HK1053125A1 (en) 2003-10-10
US7807658B2 (en) 2010-10-05
JP2006306885A (ja) 2006-11-09
IS2231B (is) 2007-04-15
US20020156053A1 (en) 2002-10-24
CA2397583A1 (en) 2001-06-14
AU2036401A (en) 2001-06-18
PL364795A1 (en) 2004-12-13
US6841698B2 (en) 2005-01-11
EP1484333A1 (en) 2004-12-08
JP2003516407A (ja) 2003-05-13
NO20022728D0 (no) 2002-06-07
PT1240172E (pt) 2005-02-28
SK286904B6 (sk) 2009-07-06
KR100689144B1 (ko) 2007-03-08
HUP0300301A3 (en) 2008-12-29
KR20020060992A (ko) 2002-07-19
HK1048321A1 (en) 2003-03-28
IS6408A (is) 2002-06-06
JP3914435B2 (ja) 2007-05-16
CZ20021983A3 (cs) 2002-11-13
DE60015796T2 (de) 2005-11-03
US6576626B2 (en) 2003-06-10
HUP0300301A2 (hu) 2003-06-28
IL149840A0 (en) 2002-11-10
MY125414A (en) 2006-07-31
US20030220303A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
UY27273A1 (es) Solución oral de arilpiprazol
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
CU22774A3 (es) Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
DE69111582D1 (de) 1,4-Disubstituierte Piperazine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2102144T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima-17beta metoxi-17alfa-metoximetilo un procedimiento para su produccion y productos medicinales que contienen estos compuestos.
ES2052028T3 (es) Un metodo para preparar compuestos diarilicos anti-ateroscleroticos.
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
AR016973A1 (es) Uso de aminometil-cromanos sustituidos para la produccion de un medicamento util para el tratamiento de enfermedades neurodegenerativas y para el estimulode la regeneracion neuronal
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos
ES2139965T3 (es) Benzoilguanidinas sustituidas con grupos de caracter basico, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
ES2111871T3 (es) Nuevos derivados de aminoacidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration